Q32 Bio

Q32 Bio is developing therapies targeting powerful regulators of the innate and adaptive immune systems, to re-balance immunity in severe autoimmune and inflammatory diseases. Q32 Bio’s lead programs, focused on the IL-7R pathway and complement system, address immune dysregulation to help patients take back control of their lives.

Headquarters Cambridge, MA
Website www.q32bio.com​
Twitter @Q32Bio
Pipeline Preclinical
LinkedIn Q32 Bio​